Aims To determine if therapeutic, retrospective continuous glucose monitoring (CGM) improves HbA 1c with less hypoglycaemia in women with insulin-treated gestational diabetes mellitus (GDM).
Introduction
Gestational diabetes mellitus (GDM) is defined as glucose intolerance of variable severity with onset or first recognition during pregnancy and is associated with a higher frequency of adverse materno-fetal outcomes [1] . The incidence of GDM is increasing globally. Asian ethnicity is emerging as a recognized risk factor, with prevalence rates as high as 11.4% in Malaysia and 14% in South India [2, 3] . Poor glycaemic control in GDM has been demonstrated to increase perinatal mortality/morbidity rates [4] . Treatment of GDM has been shown to reduce serious perinatal complications, and perinatal outcomes are significantly improved with better glycaemic control [4, 5] . In particular, intensive treatment of GDM reduces macrosomia. Crowther et al. [5] reported a reduction from 21% (no treatment) to 10% (treatment), while Landon et al. [4] demonstrated that achieving blood glucose targets of 5.3 mmol/l (fasting) and 6.7 mmol/l (2-h postprandial) results in a macrosomia rate of 5.9% compared with 14.3% in the control arm.
Advantages of CGM include the ability to monitor nocturnal glucose levels and detect postprandial hyperglycaemic excursions which are the blind spots of conventional capillary blood glucose (CBG) monitoring [6, 7] . Both realtime and closed CGM use in non-gravid women with Type 1 diabetes mellitus has been shown to improve glycaemic control and reduce hypoglycaemia [8] [9] [10] [11] .
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In pregnancies complicated by diabetes, where tight glucose control is necessary to improve materno-fetal outcomes, CGM may have a role in fine-tuning management and achieving recommended targets recommended as it provides comprehensive 24-h glucose profiles encompassing postprandial glucose excursions [12] , as well as details of average time spent in hypoglycaemia, euglycaemia and hyperglycaemia for periods of 3-6 days, in comparison with 4-8 point CBG profiles [13] . A trial of retrospective CGM in women with pre-gestational diabetes by Murphy et al. [14] , demonstrated that those who received CGM during pregnancy had better glycaemic control with lower HbA 1c and reduced macrosomia risk compared with women who received regular antenatal care. The recently published CONCEPTT trial also demonstrated improved neonatal outcomes in women with Type 1 diabetes who used realtime CGM [15] . The American Association of Clinical Endocrinologists (AACE) currently recommends CGM use in pregnant women with Type 1 diabetes [16] . Several groups, in mainly observational studies, have demonstrated the diagnostic efficacy of CGM in detecting hyperglycaemia and hypoglycaemia that is missed by conventional CBG testing in women with GDM [6, 7, 12, 17] , whereas others have demonstrated that CGM use leads to changes in clinical decision-making [6, 12, 18] . Yu et al. [19] have shown that periodic 72-h retrospective CGM use in women with dietcontrolled GDM (the majority of whom were still on diet alone by trial end) improves pregnancy outcomes when compared with a control group of mothers using CBG monitoring alone. This interventional study, however, did not report HbA 1c outcomes.
To our knowledge, there have been no published trials on the efficacy of retrospective CGM in women with exclusively insulin-treated GDM, specifically examining glycaemic outcomes such as HbA 1c and hypoglycaemia during longitudinal follow-up until delivery. We therefore designed an open-label randomized controlled trial (RCT) to evaluate prospectively the therapeutic effect of retrospective CGM use in women with insulin-treated GDM. We hypothesized that professional CGM use at 4-week intervals in the second-half of pregnancy would improve glycaemic control and reduce hypoglycaemia.
Methods
This prospective, open-label, RCT enrolled 57 women with insulin-treated GDM (Fig.1 receiving multidisciplinary The inclusion and exclusion criteria are given in Table 1 . Our centre practises opportunistic universal screening during the first encounter with the obstetrician with a 75-g oral glucose tolerance test (OGTT) using diagnostic criteria of a fasting plasma glucose ≥ 5.1 mmol/l and/or a 2-h post-load plasma glucose of ≥ 7.8 mmol/l, as per local guidelines. If an early screen is negative women are re-screened at 24-28 weeks' gestation.
The main exclusion criteria were pre-gestational Type 1/ Type 2 diabetes or newly diagnosed overt diabetes in pregnancy [HbA 1c ≥ 48 mmol/mol (6.5%), fasting glucose ≥ 7.0 mmol/l, random glucose ≥ 11.1 mmol/l].
Study protocol
All women were randomized in blocks of four using sealed envelopes (with treatment allocation within) into two groups (a CGM group and a standard antenatal care only group) by a research assistant. Six women randomized into the CGM group withdrew voluntarily before the start of the study and did not undergo even a single CGM. Those who withdrew were replaced by randomly selected eligible women who consented to participate and were then randomized in the same manner, i.e. blocks of four. One woman withdrew within the first CGM, and was replaced by another woman also selected randomly. Reasons for withdrawal were religious beliefs, inability to commit to the scheduled appointments and inconvenience of wearing CGM (Fig. 1) .
Baseline demographic, anthropometric and clinical information were obtained via interview using a structured questionnaire. Every effort was made to provide equal care and education to both groups. Group 1 underwent CGM at 28, 32 and 36 weeks' gestation in addition to standard antenatal care, whereas Group 2 received only standard antenatal care. Women in the CGM group were managed
What's new?
The women in our study had gestational diabetes mellitus (GDM) treated with insulin, thus representing women with more severe disease with a higher risk of adverse materno-fetal outcomes.
We showed that the use of continuous glucose monitoring (CGM) in women with insulin-treated GDM improved glycaemic control with no significant increase in symptomatic hypoglycaemia.
CGM may have a role in improving glycaemic control in women with insulin-treated GDM, which in turn could result in better materno-fetal outcomes.
This could have important clinical implications for diabetes management, especially when GDM occurs at a higher rate in Asia.
ª 2018 Diabetes UK based on CGM and CBG data, whereas women in the control group were managed based on CBG alone. In both arms of the study, women were required to measure CBG seven times per day (fasting, preprandial, 2 h postprandial and pre-bed) at least 3 days per week. In addition, to calibrate the CGM device, those in Group 1 had to monitor CBG a minimum of four times per day during the 6 days of sensor use. All women were taught by trained diabetes nurse educators to self-monitor blood glucose and those receiving CGM were given additional training on how to use the CGM device. All women in both groups were taught to record meals, CBG values, hypoglycaemic events, insulin timing and dosage, and exercise in standardized log-sheets. As per standard in our centre, women with GDM are reviewed weekly if glucose levels are off-target and every 2 weeks if within target until 36 weeks' gestation. After 36 weeks, all women are reviewed weekly until delivery.
Similar glycaemic targets for GDM (standard of care in our centre) were used in both groups: fasting 3.5-5.0 mmol/l, premeals 4.0-5.8 mmol/l and 2 h postprandial 4.0-6.7 mmol/l. However, in the CGM group, an additional target of 1 h postprandial < 7.8 mmol/l on CGM was also used. CBG, food diaries and hypoglycaemia logs were collected for all women and reviewed at each visit. At every visit women were asked about any hypoglycaemic events that were not logged and these were also documented by the researchers. Adjustments to therapy were made if women did not achieve target glucose despite best efforts at diet modification. Women with fasting glucose < 3.5 mmol/l and non-fasting glucose < 4 mmol/l or who had symptoms of hypoglycaemia (regardless of glucose level) while on insulin had their insulin doses reduced accordingly, as per standard practice.
The CGM device used was the Medtronic iPro2 Enlite 6-day sensor which measures interstitial fluid glucose within a range of 2.2-22 mmol/l. The sensor was inserted over the abdomen on day 1 and removed day 7. During this period, CGM glucose measurements were not accessible to the women or management team.
In the group that underwent CGM, after sensor removal (day 7) at weeks 29, 33 and 37, stored CGM data were downloaded using the manufacturer's software (Carelink iPro Therapy Management Software) and printed reports were given to both the woman and endocrinologist the same day. CGM data were reviewed by the endocrinologist on the day of removal, and findings discussed with women, taking note of abnormal glycaemic patterns. Women were advised to identify any possible reasons for these patterns, and their diet, exercise and insulin dose were taken into consideration. CGM data together with CBG results were used to make therapeutic decisions.
For the purpose of data analysis, euglycaemia was defined as glucose within the range 3.5-6.7 mmol/l at any time point, however, therapeutic decision-making was modified based upon an upper limit postprandial target of 7.8 mmol/l at 1 h and not 6.7 mmol/l.
HbA 1c was measured in all women at weeks 28, 33 and 37. The HbA 1c assays were DCCT aligned and IFCC/NGSP certified. Other parameters such as weight and urine ketones were monitored at every visit. All women had fetal ultrasound scans at regular intervals as decided by the Singleton pregnancy.
Confirmed GDM (75g oral glucose tolerance test: fasting plasma glucose ≥ 5.1 mmol/l and/or 2-h glucose ≥ 7.8 mmol/l) (based on local guidelines)*.
GDM on insulin therapy.
Exclusion criteria Pre-gestational Type 1 or Type 2 diabetes.
Newly diagnosed overt-diabetes in pregnancy [HbA 1c ≥ 48 mmol/mol (6.5%), fasting glucose ≥ 7.0 mmol/l, random
Pregnancies with established fetal anomalies or possible preterm delivery secondary to maternal disease besides GDM.
Known endogenous/exogenous Cushing's syndrome.
Known chronic infections.
Definitions
Maternal hypoglycaemia: symptoms or asymptomatic biochemical hypoglycaemia (finger-stick fasting glucose < 3.5 mmol/l and non-fasting glucose < 4.0 mmol/l).
Euglycaemia on CGM: glucose levels 3.5-6.7 mmol/l. 4-24 h of life: < 1.9 mmol/l (prefeed); < 2.5 mmol/l (1 h after feed) [20] .
GDM, gestational diabetes mellitus; CGM, continuous glucose monitoring. obstetrician. Fetal parameters were monitored and plotted on customized local fetal growth charts. Birth information (mode of delivery, maternal complications) as well as neonatal outcome parameters such as birthweight, gestational age at delivery, APGAR score, hypoglycaemia, jaundice and neonatal intensive care unit (NICU) admission were retrieved from hospital files. The pre-specified primary outcome was change in HbA 1c from 28 to 37 weeks. The secondary outcome was maternal hypoglycaemia.
Power calculations
Based upon Murphy's research in women with pre-gestational diabetes [14] , a minimum sample size of 36 was required to achieve an 80% power to detect a 0.6% reduction in HbA 1c at P = 0.05. To allow for attrition, a sample size of 50 (25 per group) was decided upon.
Statistical analysis
SPSS (Statistical Package for the Social Services) IBM version 20.0 software was used for data analysis. Data are presented as means (AE SD) (continuous parametric variables), medians (Q25-Q75) (continuous non-parametric variables) and percentages (categorical data). Differences between groups were evaluated using t-test and chi-squared test. Within-group differences were evaluated with paired t-testing. Relationships between continuous variables were analysed using Pearson's correlation test. The statistical significance threshold was P < 0.05.
Results

Baseline characteristics
A total of 50 women completed the protocol ( Fig. 1 ) with 25 randomized to the CGM arm (Group 1) and 25 to the control arm (Group 2).
Baseline characteristics did not differ between groups except for an earlier gestational age at diagnosis of GDM in the CGM arm (Table 2) . Although 60% (15/25) of women in the CGM arm and 36% (9/25) in the control arm had GDM diagnosed before 20 weeks' gestation, all women were asymptomatic, had no pregravid diagnosis of hyperglycaemia and had a baseline HbA 1c < 48 mmol/mol (6.5%). Fasting and 2-h glucose levels at diagnosis of GDM were not significantly different between the two groups.
Therapy prior to study enrolment Duration and dose of metformin therapy and insulin therapy prior to enrolment were not significantly different between groups. Intensification of metformin and insulin therapy was also not different between groups. The frequency of healthcare provider contact (endocrinologist, dietitian, diabetes educator nurse) did not differ between groups prior to study enrolment (Table 2) .
Glycaemic outcomes
Both groups had a similar baseline HbA 1c 32 AE 3 mmol/mol (5.1 AE 0.3%) vs. 34 AE 6 mmol/mol (5.3 AE 0.5%), P = 0.124 ( Fig. 2 and Table 3 ). As pregnancy advanced, the CGM group had significantly lower HbA 1c levels compared with the standard care group at both 33 and 37 weeks ( Fig. 2 and Table 3 ). Mean HbA 1c remained unchanged throughout trial duration in the CGM group but rose steadily in the standard care group as pregnancy advanced. Mean change in HbA 1c from baseline (DHbA 1c ) was only + 1 mmol/mol (0.09%) in the CGM group compared with + 3 mmol/mol (0.30%) in the standard care group (P = 0.024). A significantly greater proportion of women with CGM attained HbA 1c < 40 mmol/mol (5.8%) at 37 weeks, compared with those in the standard care group (92 vs. 68%; P = 0.012). There were no differences in fasting blood glucose and CBG values between groups at any of the time points (Table 3) .
Hypoglycaemia
The majority of women in both groups experienced hypoglycaemia (symptomatic and asymptomatic) at least once after study enrolment, with a numerically greater proportion in the CGM group which was not significant (92% vs. 72%, P = 0.138). Overall hypoglycaemia frequency rates (combined symptomatic and asymptomatic) were significantly higher in the CGM group (Table 4) . However, there were no significant differences in symptomatic hypoglycaemia per person between groups. There were no episodes of severe hypoglycaemia in either group. Similar findings were seen during the last 4-week period, with more hypoglycaemia overall (both symptomatic and asymptomatic biochemical hypoglycaemia) in the CGM group, but no difference in symptomatic hypoglycaemia alone between groups (Table 4) . Most of these episodes of hypoglycaemia (94.8%) were in the range 3-4 mmol/l, and 49.5% were asymptomatic.
Insulin therapy
Total insulin requirement increased throughout pregnancy in both groups, however, the quantum increase from baseline to study end did not differ significantly between groups (CGM vs. control: 16.2 AE 6.4 vs. 11.8 AE 13.6 units, P = 0.314). Total insulin dose was also similar in both groups at baseline, 32 and 37 weeks. At baseline, 52% of women in the CGM group were on intensive insulin therapy (four or more injections per day) compared with 60% in the standard care group. However, at the end of the study, numerically, more women in the CGM group were receiving intensive insulin therapy (CGM 74% vs. standard care 56%, P = 0.195).
Intensification of insulin dose and number of injections from baseline to 37 weeks were similar in both groups. At pregnancy end, 72% of the mothers in the CGM group were on insulin analogues (either basal or bolus analogues) compared with 52% in the standard care group (P = 0.057). Both groups had equal numbers of women on metformin (76% in each group) ( Table 5 ).
Frequency of healthcare provider contact post enrolment
Frequency of contact with the endocrinologist, dietitian and diabetes educator nurse post enrolment was not significantly different between groups (Table 5 ).
Maternal and fetal outcomes
All women delivered by 38 weeks with the exception of three preterm deliveries from the CGM group (at 32, 35 and 36 weeks respectively) and one from the control group at 36 weeks. Birthweight was non-significantly higher in the standard care group compared with the intervention group (Table 6 ).
Continuous glucose monitoring
Some 23 of 25 women in the intervention group underwent the three scheduled CGM measurements. The other two women had preterm deliveries at 32 (completed first CGM only) and 35 weeks (completed first and second CGM only) respectively. The third woman who had a preterm delivery at 36 weeks was able to complete her third CGM. As pregnancy advanced, percentage time in euglycaemia increased with a concurrent reduction in time in hyperglycaemia. The CGM area under the curve (AUC) above-limit (> 6.7 mmol/l) was also significantly reduced from the first to third CGM measurement. There was no significant change in time spent in hypoglycaemia between the first and third CGM measurements (Table 7) . A mean of 21.4 h/week of hyperglycaemia (glucose > 6.7 mmol/l) was detected by the first CGM measurement but missed by CBG.
Discussion
We have demonstrated that additional use of CGM in women with insulin-treated GDM improves glycaemic control as evaluated by DHbA 1c , when compared with standard antenatal care with self-monitoring of CBG alone. DHbA 1c from enrolment at 28 weeks' gestation to trial end was significantly lower in the intervention group than in the standard care group (P = 0.024). Over the course of pregnancy, CGM use was associated with a reduced time in hyperglycaemia without increasing time in hypoglycaemia, suggesting that the improvement in glycaemic control as measured by HbA 1c was real. At delivery, more mothers with GDM who used CGM achieved an HbA 1c < 40 mmol/mol (5.8%) compared with mothers receiving standard care (92% vs. 68%, P < 0.05). This improvement in HbA 1c might have been secondary to a greater awareness of hyperglycaemia in the CGM arm, perhaps leading to greater intensification of insulin therapy by the endocrinologist, and possibly more intensive diabetes self-management by the women. The CGM sensor detects hyperglycaemia over the entire postprandial period, in contrast to CBG which evaluates discrete post-meal time points, thus often missing peak prandial hyperglycaemia. In our study, a mean of 21.4 h/week of hyperglycaemia (glucose > 6.7 mmol/l) was detected by the first CGM measurement but missed by CBG. Although mean total insulin dose was similar in both groups at delivery, more women in the CGM group were on FIGURE 2 Mean HbA 1c at 28, 33 and 37 weeks in CGM and standard care group. *Compared with week 28, P = 0.016. †Compared with week 28, P < 0.001. ‡Compared with week 33, P = 0.001. basal-bolus therapy compared with those receiving standard care (P = not significant).
There have been a few other parallel-arm RCTs evaluating therapeutic, retrospective CGM use in pregnancy [14, 19, 21] . To our knowledge, this is the first to focus exclusively on women with insulin-treated GDM using the 6-day sensor. Our trial is also the first to report details of concomitant insulin-therapy adjustments with CGM use and focus on HbA 1c outcomes in GDM. Murphy et al. [14] , studied higher-risk mothers with pre-gestational diabetes, finding reductions in HbA 1c with retrospective CGM use which began to emerge at 28-32 weeks with a final difference of 6 mmol/mol (0.6%) resulting in reduced macrosomia rates in the CGM arm. These women began CGM use earlier in pregnancy because they had established diabetes, thus undergoing more periods of monitoring (mean: 4.2 times over 24 weeks). The women in study, however, utilized CGM three times over 9 weeks (from 28 weeks' gestation), yet demonstrated a significant 4 mmol/mol (0.4%) lowering of HbA 1c in the intervention arm. By contrast, Secher et al. [21] evaluated the use of periodic real time CGM in pre-gestational diabetes (Type 1 and 2) finding no differences in pregnancy outcomes, hypoglycaemia and HbA 1c compared with standard care. These women had good glycaemic control similar to the standard care group, thus CGM might not have been able to effect much change. The recently published CONCEPTT trial [15] studied real-time CGM use in 215 women with Type 1 diabetes recruited before 13 weeks' gestation. They found a modest reduction in HbA 1c of 2 mmol/mol (0.19%) ª 2018 Diabetes UK in the CGM group at 34 weeks, with less time spent in hyperglycaemia; similar to our findings in GDM. Moreover, they were able to demonstrate improvements in the neonatal outcomes of large for gestational age (LGA), hypoglycaemia and ICU stay. Yu et al. [19] evaluated therapeutic, retrospective CGM in 336 women with GDM (~20% of whom required insulin by trial end). This Chinese trial compared glycaemia in both arms with 72-h CGM assessment at two time points, during the first and fifth week of the trial, but only used sensor data in the intervention arm to make management decisions. The trial compared supplementary therapeutic, retrospective 72-h CGM use at regular 2-4-week intervals with CBG seven times daily alone (from recruitment at~26 weeks' gestation until delivery) and found significantly lower glycaemic variability, shorter periods of hyperglycaemia and hypoglycaemia (< 3.3 mmol/l) in the intervention arm after 5 weeks of CGM use. These differences in glycaemia as evaluated by CGM parameters were associated with lower infant birthweight, macrosomia and
LGA rate, and a composite neonatal outcome rate in the CGM intervention arm [19] . However, the effect of CGM on change in HbA 1c by end of pregnancy was not reported. The role of HbA 1c in monitoring glycaemia in GDM is not well-established. Current National Institute of Health and Care Excellence (NICE) guidelines recommend its use to assess risk only in mothers with pre-gestational diabetes [22] . The reliability of HbA 1c in pregnancy has been questioned due to confounding factors such as dilutional anaemia and shortened erythrocyte lifespan [23] . Recent post hoc analysis of two trials of CGM in pre-gestational diabetes has validated HbA 1c as a measure of average glycaemia, albeit with a smaller estimated average blood glucose of 0.67 mmol/l per 11 mmol/mol (1.0%), compared with 1.0-2.0 mmol/l per 11 mmol/mol (1.0%) in stable non pregnant people with Type 1 and 2 diabetes [24] . Several key papers have linked higher HbA 1c in GDM in both the second and third trimesters with greater likelihood of macrosomia and adverse perinatal outcomes. Lowe et al. [25] found that HbA 1c at 24-32 weeks' gestation in GDM (after adjustments for age, BMI, etc.) was independently predictive of macrosomia, with an odds ratio of 1.93 in women with an HbA 1c > 40 mmol/mol (5.8%), compared with an HbA 1c < 26 mmol/mol (4.5%). Another study showed that women with GDM with HbA 1c > 34 mmol/mol (5.3%), either at diagnosis or pre-delivery, experienced more pregnancyrelated adverse events [26] . Despite our small sample population, which was powered to demonstrate significant differences in glycaemic outcomes but not materno-fetal outcomes, birthweight and lower segment caesarean section rates were non-significantly lower in the CGM group. Extrapolating from the Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO) study results, we can postulate that the lower mean HbA 1c of < 33 mmol/mol (5.2%) in our CGM group, could have resulted in lower macrosomia rates and perinatal complication rates with a larger sample size [25, 26] . Both our study arms achieved CBG similar to the landmark GDM trial by Landon et al. [4] . However, HbA 1c is a better integrated measure of glycaemia than CBG profiles or the periodic CGM utilized by Yu et al. [19] . Although HbA 1c reflects average glycaemia over 8-12 weeks, and therefore the outcome measure we used may have included the glycaemic period before enrolment at 28 weeks, it is well established that the last 30 days of glycaemia has the greatest impact on glycation [27] . Therefore, the progressively increasing HbA 1c in late pregnancy as seen in our standard care group, may imply deteriorating glycaemic control in late pregnancy as seen in other studies [14, 15, 21] . In addition, as our primary outcome was change in HbA 1c from 28 to 37 weeks, this reduces the possibility that the significant difference in DHbA 1c between the groups could be substantially affected by pharmacotherapy or lifestyle modification prior to enrolment at 28 weeks, despite the fact that a proportion of women had GDM diagnosed before 20 weeks' gestation. In addition, baseline HbA 1c at enrolment (28 weeks' gestation) was not significantly different between the two arms, thus making it likely that any subsequent change in HbA 1c was secondary to the CGM intervention.
There is little consensus on how to define 'hypoglycaemia' in pregnancy, with few studies reporting hypoglycaemia rates in women with insulin-treated GDM. The biochemical hypoglycaemia threshold of 4.0 mmol/l in our trial was chosen because it is similar to that used in management of non-gravid women with Type 1 and 2 diabetes on pharmacological treatment [28] . Although NICE 2015 guidelines recommend keeping blood glucose above 4.0 mmol/l in insulin-treated diabetes in pregnancy [22] , there is no guidance from the American Diabetes Association (ADA) on lower limits of desirable blood glucose in GDM [29] .
We found a higher incidence of hypoglycaemia in the CGM group compared with the standard care group, especially in the last 4 weeks of the trial. Some 94.8% of hypoglycaemia episodes with concomitant CBG had readings in the range of 3-4 mmol/l. However, as interstitial glucose levels are known to drop as low as 2.8 mmol/l in healthy pregnancies [30, 31] and previous studies have used cut-offs as low as 2.7 mmol/l to diagnose hypoglycaemia in pregnancy [7, 32] , it is difficult to ascertain whether these mainly asymptomatic reduced glucose readings are of clinical significance. By contrast, symptomatic hypoglycaemia, which may have more clinical relevance in pregnancy, was similar between groups. None of the women had severe hypoglycaemia. Importantly, CGM parameters available only in the intervention group demonstrate improvement in glycaemia with no increased time in hypoglycaemia, indicating that women were not more hypoglycaemic because of better glycaemic control. The improvement in euglycaemia over time can be explained by a reduction in time in hyperglycaemia. Of note, there were no small for gestational age babies in either arm and gestational weight gain in both groups was similar and as per Institute of Medicine recommendations [33] , indicating that improved glycaemic control in the intervention arm was not at the expense of reduced calorie intake. We used CBG to enable valid comparisons of hypoglycaemia outcomes between groups as this was utilized by both. This is a limitation of our study design, as it is possible that standard care might have had episodes of low glucose missed by CBG. Yu et al. [19] used CGM in both groups, finding that time spent in hypoglycaemia was more than fivefold higher in standard care compared with the intervention arm. However, CGM is less reliable when it comes to the lower range of glucose values [34] .
To our knowledge, this is the first prospective, RCT of therapeutic CGM use exclusively in insulin-treated GDM, focusing on HbA 1c and hypoglycaemia. Efforts were made to ensure both treatment arms received equal care in terms of follow-up, dietary and diabetes nurse educator advice, and optimization of insulin based on the glycaemic profiles available. We were limited both by a small sample size, and, as a single centre study where both participant/clinical ª 2018 Diabetes UK practitioner were unblinded perhaps introducing bias. Many of our women were diagnosed with GDM at an early gestation (< 24 weeks), having been screened early, as our centre practises opportunistic universal screening during the first encounter with the obstetrician. Although none had a prior history of diabetes, this might indicate a proportion had undiagnosed pre-gestational glucose intolerance. Diagnosis of GDM was significantly earlier in the CGM group and consequently there was a longer total duration of medical-nutrition/pharmacological therapy among those with earlier diagnosis in the intervention arm, raising the possibility that these differences might have contributed to improved glycaemic control in the CGM arm. There were, however, no significant differences in mean duration, dose and intensification of pharmacological therapy between the two groups prior to study enrolment. Although we did not collect data on actual frequency of CBG monitoring, it is theoretically possible that the CGM arm had potentially more CBG because they were required to monitor levels at least four times a day during each of the three 6-day CGM periods. These factors could also have contributed to improved glycaemic outcomes in the intervention arm. Our findings may not be generalizable to a setting where clinical guidelines mandate more frequent CBG such as seven points/day as recommended by NICE [22] .
In conclusion, we found that therapeutic CGM use just three times in the third trimester in insulin-treated GDM and its associated intensive care, safely and effectively lowers HbA 1c to a greater extent than standard antenatal care with CBG monitoring alone, without any increase in severe hypoglycaemia. Our findings suggest that CGM is a useful and safe tool in the management of women with insulintreated GDM.
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